For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Shareholders who purchased shares of EPIX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required ...

Transdermal estradiol patches may be an alternative to LHRHas when combined with ARPIs to treat mHSPC, researchers say.

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is ...

Renal + Urology News highlighted research led by the University of Cincinnati's Alberto Martini, MD, that found using ...

New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.